Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aconitine is a highly toxic diterpene alkaloid derived from plants of the *Aconitum* genus, such as *Aconitum napellus* (monkshood) and *Aconitum carmichaelii* (Fuzi). It is a potent neurotoxin and cardiotoxin that functions by binding with high affinity to Site 2 of voltage-gated sodium channels, preventing their inactivation and causing persistent depolarization of excitable membranes. This action results in severe arrhythmias, respiratory failure, and neurological symptoms. In Traditional Chinese Medicine (TCM), aconitine-containing preparations like 'Fuzi' are used for their analgesic and anti-inflammatory properties in treating rheumatoid arthritis and chronic pain, though they require rigorous processing (such as boiling) to hydrolyze aconitine into less toxic derivatives like benzoylaconine and aconine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aconitine.